The use of biomarkers in the patient with heart failure - PubMed

Review

The use of biomarkers in the patient with heart failure

Punam Chowdhury et al. Curr Cardiol Rep. 2013 Jun.

Abstract

Heart failure is a major burden to the health care system in terms of not only cost, but also morbidity and mortality. Appropriate use of biomarkers is critically important to allow rapid identification and optimal risk stratification and management of patients with both acute and chronic heart failure. This review will discuss the biomarkers that have the most diagnostic, prognostic, and therapeutic value in patients with heart failure. We will discuss established biomarkers such as natriuretic peptides as well as emerging biomarkers reflective of myocyte stress, myocyte injury, extracellular matrix injury, and both neurohormonal and cardio-renal physiology.

Similar articles

• Novel biomarkers in heart failure with preserved ejection fraction.

  Shah KS, Maisel AS. Shah KS, et al. Heart Fail Clin. 2014 Jul;10(3):471-9. doi: 10.1016/j.hfc.2014.04.005. Heart Fail Clin. 2014. PMID: 24975910 Review.

• Novel biomarkers in acute heart failure.

  Yanavitski M, Givertz MM. Yanavitski M, et al. Curr Heart Fail Rep. 2011 Sep;8(3):206-11. doi: 10.1007/s11897-011-0065-5. Curr Heart Fail Rep. 2011. PMID: 21681444 Review.

• Biomarkers of heart failure with normal ejection fraction: a systematic review.

  Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, Boersma E, Kardys I. Cheng JM, et al. Eur J Heart Fail. 2013 Dec;15(12):1350-62. doi: 10.1093/eurjhf/hft106. Epub 2013 Jul 11. Eur J Heart Fail. 2013. PMID: 23845797 Review.

• Soluble ST2 and galectin-3 in heart failure.

  Shah RV, Januzzi JL Jr. Shah RV, et al. Clin Lab Med. 2014 Mar;34(1):87-97, vi-vii. doi: 10.1016/j.cll.2013.11.009. Epub 2014 Jan 14. Clin Lab Med. 2014. PMID: 24507789 Review.

• State of the Art: Newer biomarkers in heart failure.

  de Boer RA, Daniels LB, Maisel AS, Januzzi JL Jr. de Boer RA, et al. Eur J Heart Fail. 2015 Jun;17(6):559-69. doi: 10.1002/ejhf.273. Epub 2015 Apr 16. Eur J Heart Fail. 2015. PMID: 25880523 Review.

Cited by

• Clinical Significance of B-type Natriuretic Peptide in Heart Failure.

  Yoo BS. Yoo BS. J Lifestyle Med. 2014 Mar;4(1):34-8. doi: 10.15280/jlm.2014.4.1.34. Epub 2014 Mar 31. J Lifestyle Med. 2014. PMID: 26064852 Free PMC article. Review.

• Baseline mitochondrial DNA copy number and heart failure incidence and its role in overall and heart failure mortality in middle-aged women.

  Sundquist K, Sundquist J, Wang X, Palmer K, Memon AA. Sundquist K, et al. Front Cardiovasc Med. 2022 Nov 10;9:1012403. doi: 10.3389/fcvm.2022.1012403. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36440036 Free PMC article.

• Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?

  Hinder M, Yi BA, Langenickel TH. Hinder M, et al. Clin Pharmacol Ther. 2018 May;103(5):802-814. doi: 10.1002/cpt.1010. Epub 2018 Feb 1. Clin Pharmacol Ther. 2018. PMID: 29315510 Free PMC article. Review.

• Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases.

  Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, Matsuo M, Hatano Y, Tomita H. Hara A, et al. Biomolecules. 2020 Mar 3;10(3):389. doi: 10.3390/biom10030389. Biomolecules. 2020. PMID: 32138174 Free PMC article. Review.

• Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology.

  Hara A, Niwa M, Kanayama T, Noguchi K, Niwa A, Matsuo M, Kuroda T, Hatano Y, Okada H, Tomita H. Hara A, et al. Biomolecules. 2020 Sep 4;10(9):1277. doi: 10.3390/biom10091277. Biomolecules. 2020. PMID: 32899694 Free PMC article. Review.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information